chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Severe headache, the day following the administration of the second dose.; Fever, the day following the administration of the second dose.; Joint pain, the day following the administration of the second dose.; Body aches, the day following the administration of the second dose.; Radical change in my temperament/ Intense rage, the following week.; Irritable; This is a spontaneous report from a non-contactable consumer, the patient. A 25-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration in right arm in Mar2021 (at the age of 25-years-old) as a single dose for COVID-19 immunisation. The patients medical history was not reported. The patient had not been diagnosed with COVID-19 prior to the vaccination. The patient had not tested for COVID-19 since the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN), via an unspecified route of administration on an unknown date in Feb2021 as a single dose for COVID-19 immunisation. On an unknown date in Mar2021, the day following the second dose, the patient had experienced severe headache, fever, join pain and body aches. The following week, the patient had experienced anger/rage and irritability. The patient had noticed a radical change in his temperament. The patient was then very irritable, and prone to fits of intense rage. The patient never had anger issues in the past, or and any other psychiatric issues. The patient was hoping this as temporary issue, but right then, it was quite debilitating. The patient did not receive any treatment for the events. The clinical outcome of all the events headache, fever, join pain body aches, anger/rage and irritability was not recovered at the time of report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
38 y.o. female previously healthy, received yellow fever vaccine and TWINRIX (Hep A&B) vaccines on May 16, 2008 presents today complaining of generalized muscle aches and weakness.  Reports she felt well after the vaccines until 5/21/08 when she developed pain in right arm, and mild achy all over.  She contacted me yesterday because she was concerned she was feeling worse, nauseated, and overall not improving.  She denies any fever or sweats.
Pain in Legs; Pain in her abdomen; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a patient and describes the occurrence of PAIN IN EXTREMITY (Pain in Legs) and ABDOMINAL PAIN (Pain in her abdomen) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (Pain in Legs) and ABDOMINAL PAIN (Pain in her abdomen). At the time of the report, PAIN IN EXTREMITY (Pain in Legs) and ABDOMINAL PAIN (Pain in her abdomen) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medication were reported.  No treatment medication were reported.
PATIENT REPORTED FEELING WARM, NAUSEATED, VOMITTING, LIGHT HEADED AND DIAPHOTRETIC. PATIENT STED SHE TOOK ZOLOF THIS MORNING AS HE HAS PANIC ATTACKS.  PATIENT REPORTED TO FEEL BETTER AFTER VOMITTING  AND  KNEW THAT THE VOMITTING WAS DUE TO PANIC ATTACK AS THIS IS THE SYMPTOM THAT MANIFEST  DURING THE EPISODE OF PANIC ATTACK. O PATIENT WAS INSTRUCTE TO  WAIT OUT 15 MINUTES AND NOTIFY OBSERVER IF SYMPTOMS  OCCUR OR WORSEN
Pain in both my thumbs; Mild nausea; Runny nose; Extreme tiredness; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8739) via an unspecified route of administration in the left arm on 14Apr2021 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy to penicillin sulfa and hops. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any concomitant medications. On 15Apr2021 at 15:00, the patient experienced pain in both thumbs, mild nausea, runny nose and extreme tiredness. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken for the reported events. Since the vaccination, the patient had been tested for COVID-19. On 15Apr2021, the patient underwent PCR test (Nasal Swab: test type) and the result was found to be negative. The clinical outcome of the events pain in both thumbs, mild nausea, runny nose and extreme tiredness were resolved on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Extreme pain at injection site and shoulder. Felt very hot and nauseous; fainted; chills for about 4-5 hours after. Fatigued for following two days.
No adverse event. Patient did not report any symptoms. Advised patient to monitor for symptoms and call clinic if needed.
two arm plaques; This spontaneous case was reported by a physician and describes the occurrence of SKIN PLAQUE (two arm plaques) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced SKIN PLAQUE (two arm plaques). At the time of the report, SKIN PLAQUE (two arm plaques) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided. No treatment medication were provided.   This case was linked to MOD-2021-327033 (Patient Link).   Reporter did not allow further contact
screaming, high pitched cry, excessive sleepiness, local redness & swelling, extremely sensitive to light & noise, did not want to be moved, would not eat, fever >103; sxs lasted about 8-10hrs; APAP q 2-3hrs; recovery appears to be complete
This spontaneous report as received from a nurse refers to a male patient of unknown age. The patient was vaccinated with a first dose of M-M-R II on 24-MAY-1991. Lot number, dosing information and route of administration were not provided. A second dose of M-M-R II was vaccinated on 02-AUG-2002. Lot number, dosing information and route of administration were not provided. A rubella titer was performed on an unspecified date after the second dose of M-M-R II and the patient was found to have a negative titer. A third dose of M-M-R II was administered on 26-JUN-2013. Therapy type, lot number, dosing information and route of administration were not provided. Another rubella titer was performed on 02-JUL-2013. The result of the titer were negative. Patient sought medical attention and went to the physician's office. The event outcome was reported as not recovered/not resolved. Causality assessment was not provided. Additional information has been requested.
My symptoms started with sinus congestion and runny nose. I thought I had a head cold. I tested positive for COVID-19 on October 20, 2022. I called my doctor. They called me back and asked me a lot of questions. I sent a copy of the test result to them through the portal. They said it was too late for the antiviral medication. They recommended molnupiravir. I took four pills twice a day for 5 days. I took another COVID-19 test this past Monday and still tested positive. I still have a headache, congestion, runny nose, and exhaustion. This morning, I tested positive again.
Flu shot 10/28. Not feeling well just after getting flu shot. Fine red itchy rash all over body which developed yesterday. Reports throat is itchy but able to swallow with no difficulty. Symptoms: Skin rash, Treatment Drugs used: DIPHENHYDRAMINE dose 25 units: MG Freq: PRN Route; PO, HYDROCORTISONE dose: Units: Freq: PRN Route: TOP
received a dose / where the diluent was correctly administered, but the powder was expirated since July 2020; This case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a adult male patient who received Men ACWY-CRM NVS (Menveo) (batch number amva1738, expiry date 31st July 2020) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.  Additional details were provided as follows: Age at vaccination was not reported. Nurse reported that the patient received a dose of Menveo where the diluent was correctly administered, but the powder was expirated since July 2020, which led to  expired vaccine used. The reporter consented to follow up.
This spontaneous report was received from a consumer, the patient's son and refers to a 79-year-old female patient. No information regarding the patient's pertinent medical history, concomitant medications, drug reactions or allergies was provided. On an unknown date in 2013, 4 years ago, the patient was vaccinated with ZOSTAVAX (dose, frequency, rout eof administration, lot# and expiration date were not reported) for prevention from shingles. On an unknown date, approximately in November 2017, reported as 3 weeks ago, the patient experienced a severe case of shingles. The outcome of herpes zoster was unknown. The relatedness between the event and therapy with ZOSTAVAX was not reported.
Employee received PPD on (R) forearm & seasonal Influenza vaccination (L) forearm in AM. (R) forearm site became red, raised & painful after 6 hours later & also was tingling & itching. Took BENADRYL po without relief. Now also with neck, back & (R) arm itching & fine red rash with some dizziness, nausea & sweating 24 hrs later 10/6/10 approximately 9AM. No breathing issues will try ATARAX 25mg q 4-6hrs & F/U 10/6/10. 10/7/10 blurry vision & malaise persists. Pruritic sx improved. ? optic neuritis.
Receiving doses from an expired vial; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Receiving doses from an expired vial) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047c21a) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Nov-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Receiving doses from an expired vial). On 09-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Receiving doses from an expired vial) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No Concomitant medications were provided by the reporter. No Treatment information was reported. 26 patients received doses from a vial lot the Moderna COVID19 vaccine with expiration date 07 Nov 2021 on the 09 Nov 2021. HCP mentioned that the boxes didn't have an expiration date and that they were told that the vials expired 6 months after receiving the shipment.   Most recent FOLLOW-UP information incorporated above includes: On 09-Nov-2021: Follow up document received contains No New Information.
Fever started at pm 10/08/2001 100.3 degrees, vomiting morning 10/09/2001 x 3. lasted < 24 hours. Reddened left arm (site DTAP, IPV) 10 x 7 cm bruise 1 x 1cm
Redness; Itching; Red spots; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of ERYTHEMA (Redness), RASH MACULAR (Red spots) and PRURITUS (Itching) in a 77-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012L20A) for COVID-19 vaccination.     The patient did not have any history of allergies.     On 06-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jan-2021, the patient experienced RASH MACULAR (Red spots). On 17-Jan-2021, the patient experienced PRURITUS (Itching). On 19-Jan-2021, the patient experienced ERYTHEMA (Redness). The patient was treated with CORTISONE (topical) for Adverse event, at a dose of UNK dosage form. At the time of the report, ERYTHEMA (Redness), RASH MACULAR (Red spots) and PRURITUS (Itching) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient's weight was reported as "159" (units not reported). Concomitant medication was not reported. Treatment included antibiotic cream. The patient visited Physician on 19-Jan-2021 and recommended Zyrtec (was not administered).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
This spontaneous report was received from a medical assistant and refers to a multiple unspecified patients of unknown demographics. The patients' medical history, concurrent conditions and concomitant therapies were not reported. Since 25-NOV-2015, the patients were vaccinated with improperly stored doses of PROQUAD (rHA) lot # L019998, expiration date: 02-DEC-2016 (dose and route were not provided). No adverse effects were reported. The temperature stability information was reported as follows: Temperature: 19F; time frame: 2 hours; there was no previous temperature excursion, there were back in range and there was no call because of a "data logger". This is one of several reports from the same reporter. Additional information has been requested.
her blood pressure is 188/90; bad headache; This is a spontaneous report from a contactable consumer. An 83-year-old female patient  received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL1283), via an unspecified route of administration in right arm on 10Jan2021 at a single dose for protection from the virus. Medical history included a month ago on Dec2020, she fell on her right knee and has gotten a shot in her knee for pain. She was going to chiropractor and then started going to an orthopedic doctor. That is when she got a shot in her knee. She had an appointment with her doctor on 29Dec2020. She had labs a week prior. The patient's concomitant medications were not reported. The patient received Covid-19 vaccine on Sunday, 10Jan2021. Yesterday, 12Jan2021, she started having a bad headache. She took Tylenol and it went away. This am of 13Jan2021 at 7:00am, she started having a terrible headache. She also checked her blood pressure and it was 188/90. She took Tylenol around 7:15-7:30. She still has a headache. The outcome of the event headache was not recovered. the outcome of the event blood pressure and it was 188/90 was unkown.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. On 09-JUL-2018 the patient was vaccinated with an improperly stored dose of VAQTA (lot # R003739, exp date 17-MAR-2019) (dose not reported) intramuscularly. There was a data logger issue reported. The temperature of excursion was 32 degrees F up to 35 degrees F (multiple excursions) for a time frame of 13 hours. No adverse effects were reported. This is one of several reports received from the same source. Sender's Comments: US-009507513-1807USA004813; US-009507513-1807USA010174; US-009507513-1807USA010175; US-009507513-1807USA010176; US-009507513-1807USA010177; US-009507513-1807USA010178; US-009507513-1807USA010214.
Swelling, redness and itching at injection site. Tenderness and swelling in axillary region on same side as injection.
Within 2 hrs, arm swelled, hard at injection site, red at injection site, joints sore on left side of body. 4 hrs, joints all over body hurt. 6 hrs, muscle pain with weakness all over. 12 hrs, rapid pulse, rapid shallow breath, fever, chills. 18 hrs, continued pain all over, jaw locked or nearly so, much perspiration. Effects slowly reduced through next day. Second day nearly back to normal.
After a normal week with only slight effects, on the 9th day I noticed itching and reddening, with some hives. I applied cold compresses, took aspirin. It worsened over the next 24 hours, covering a larger part of my upper arm, and I applied Cortisone, took Advil, and continued with ice packs. It has calmed down over the next four days and there is now a slight ring of reddish skin, with a small patch more inflamed. Much better, but not gone, so I am still doing the care routine. Talked to a pharmacist and she said this is the right course.
No adverse event; On 10 May 2023, 27 patients received 0.25ml of the Moderna bivalent vaccine and later on 12 May 2023, 18 pts received an additional 0.25ml; This spontaneous case was reported by a pharmacist and describes the occurrence of PRODUCT ADMINISTRATION ERROR (On 10 May 2023, 27 patients received 0.25ml of the Moderna bivalent vaccine and later on 12 May 2023, 18 pts received an additional 0.25ml) and NO ADVERSE EVENT (No adverse event) in an elderly patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 067H22A) for COVID-19 prophylaxis.     It was unknown if the patient had acute illnesses at the time of vaccination and up to one month before. It was unknown if the patient had chronic or long-standing health conditions.    On 10-May-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .25 milliliter. On 12-May-2023, received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to .25 milliliter. On 12-May-2023, the patient experienced PRODUCT ADMINISTRATION ERROR (On 10 May 2023, 27 patients received 0.25ml of the Moderna bivalent vaccine and later on 12 May 2023, 18 pts received an additional 0.25ml). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT ADMINISTRATION ERROR (On 10 May 2023, 27 patients received 0.25ml of the Moderna bivalent vaccine and later on 12 May 2023, 18 pts received an additional 0.25ml) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for PRODUCT ADMINISTRATION ERROR (On 10 May 2023, 27 patients received 0.25ml of the Moderna bivalent vaccine and later on 12 May 2023, 18 pts received an additional 0.25ml).    This case was for 8th patient out of 27 patients. Patients was an over the age of 65 years.  Concomitant medications were not reported.  It was unknown if the patient was taking any prescriptions, over-the-counter medications, dietary supplements, or herbal remedies at time of vaccination or at the time of the adverse event.  The vaccine was administered in the deltoid site. On 11-May-2023 26 patients were contacted, on 12-May-2023 18 patients received an additional 0.25ml, 2 patients made appointments to receive the following week and 1 declined to receive the additional 0.25ml dose. A husband and wife pair stated that they would go to the clinic to receive the additional dose but gave no specifics and one patient was mailed a letter as he was not able to be reached by phone.   Treatment information was not reported.   This case was linked to US-MODERNATX, INC.-MOD-2023-723833 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-723833:Master case
Headache, Fever, CoughWheeze, Nausea Vomiting, body aches, slight soreness and swelling around injection site reported mild symptoms. Will treat at home with OTC meds
I never had the Pfizer vaccine. I only had the Moderna COVID-19 vaccines.; severe pain all night long; throat was scratchy; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A female patient received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), in 2023 as dose number unknown (initial pfizer dose), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Moderna covid-19 vaccines, for Covid-19 immunization. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious) with onset 2023, outcome "unknown", described as "I never had the Pfizer vaccine. I only had the Moderna COVID-19 vaccines."; PAIN (non-serious) with onset 2023, outcome "not recovered", described as "severe pain all night long"; THROAT IRRITATION (non-serious) with onset 2023, outcome "not recovered", described as "throat was scratchy".  Additional information: The patient only had the Moderna COVID-19 vaccines previously. She had a terrible reaction from Pfizer COVID-19 vaccine. She stated that she gave all her vaccination cards and she said she received Moderna previously but they still gave her Pfizer COVID-19 vaccine. She stated that she was in so much pain and as soon as she received the vaccine her throat was scratchy. It advanced to be bad and still scratchy at the time of reporting. She was in severe pain all night long.   The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.
10-22-14 - fever, area red and raised. 10-23-14 - fever, area red and raised. 10-24-14 - area only red (size 5" x 2 1/2").
After the first 15 minutes started to feel very dizzy,  30 minutes after the shot depression and darkness came over me and lasted for about 90 minutes, still dizzy and felt like I was drunk plus my shoulder felt tight and heavy.   Depression left after 1,5 hours , started to feel manic episode for 5 hours with racing thoughts, restlessness, irritation, anger, and not calm.  Still dizzy, had chills.  The next day and the day after that felt fatigued and not well, the place of a shot hurt.
nausea; fever-like chills with no temperature; This spontaneous case was reported by a non-health professional and describes the occurrence of CHILLS (fever-like chills with no temperature) and NAUSEA (nausea) in a 24-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 29-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On 30-Apr-2021, the patient experienced CHILLS (fever-like chills with no temperature). On an unknown date, the patient experienced NAUSEA (nausea). At the time of the report, CHILLS (fever-like chills with no temperature) and NAUSEA (nausea) outcome was unknown.            No relevant concomitant medications were reported. Treatment Medications were not provided by the reporter.
Four days post vaccine, associate started to get a pulsating headache.  Two days later while at work,  started to get a pounding headache, by noon started to get chest pain and felt dizzy.  Went to the ER, did an EKG and blood work to rule out a stroke.  has an appointment with an allergist and a brain scan.